Notizie Newsletter
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs
The large-scale genetic profiling of tumours can identify potentially actionable molecular variants for which approved anticancer drugs are available. However, when patients with such variants are treated with drugs outside of their approved label, successes and failures ...Leggi tutto
New ASCO System Confronts Lack of EHR Interoperability
Oct 3, 2019 - With the recent launch of a free, open-source system for standardizing the electronic storage of patient records, the American Society of Clinical Oncology (ASCO) hopes to improve information flow across electronic health record (EHR) platforms and curtail ...Leggi tutto
FDA Updates Neratinib Label in HER2+ Breast Cancer
Oct 3, 2019 - The FDA has approved a labeling supplement for neratinib for the extended adjuvant treatment of patients with HER2-positive early-stage breast cancer. The labeling supplement includes safety information based on interim results of the phase II CONTROL trial ...Leggi tutto
FDA Grants Niraparib Breakthrough Designation for BRCA+ mCRPC
Oct 3, 2019 - The FDA has granted a breakthrough therapy designation to the PARP inhibitor niraparib for the treatment of patients with BRCA1/2–mutant metastatic castration-resistant prostate cancer (mCRPC) who have previously received taxane-based chemotherapy and ...Leggi tutto
How to ensure that novel analytic methods are fit for decision-making
Oct 2, 2019 - The past decade has seen the increased generation and availability of new data sources such as real-world evidence, as well as patient-level data from completed randomised clinical trials. While these data provide an opportunity to learn more about a medicine’s ...Leggi tutto